Investors working with Cystic Fibrosis Canada are helping to support a new clinical study by Laurent Pharmaceuticals into its first-in-class lipid modulator, LAU-7b, targeting the compromised immune-inflammatory response in cystic fibrosis (CF). The financing will be used to prepare a Phase 2 clinical trial of LAU-7b in CF patients in both the United States and…
